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Science & SocietyIncreases in human lifespan worldwide have revealed
that advancing age is the predominant risk factor for
major life-threatening diseases. Recent work has shown
that ageing in diverse animals, including humans, is
malleable to specific types of genetic mutation, diet,
and drugs that can extend lifespan and improve health
during ageing. These findings point to the prospect of
broad-spectrum preventive medicine for the diseases of
ageing based on intervention in relevant aspects of the
ageing process itself.
Rising life expectancy
Human populations in developed countries, and in many
developing ones, are getting older. Human life expectancy
at birth has been increasing by about 2.5 years per decade
since the middle of the 19th century, with no demographic
hint so far of an intrinsic limit to human lifespan [1]. This
sustained trend has been brought about by successive
contributions from lifestyle and medical care, including
improvements in water and food quality and the preven-
tion of many infectious diseases, which is particularly
important for increased survival in children. Recently,
improvements in medical care have played an important
role, with increasing survival now occurring almost entire-
ly in older age groups, although there is growing evidence
that these health benefits are not evenly distributed across
different sections of the population [2].
Although increases in health and lifespan are to be
celebrated, they come with several downsides. Some of
these are economic. In many countries increased lifespan
is accompanied by falling birth rates and hence a rapid
increase in the proportion of the population that does not
participate in the labour force. There is also debate about
the extent to which increasing lifespan is also increasing
health span [3]. However, the main problem of longer
lives is that increasing age is proving to be the major risk
factor for all of the common chronic and killer conditions
of the developed world: metabolic, cardiovascular, and
neurodegenerative disease and cancer [4]. The major
burden of ill health is hence now falling on the older
section of the population and their carers and there is an
urgent need to find ways of keeping people healthy for
longer.1043-2760/
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signalling.Ageing is a malleable process
Because ageing is the major risk factor for all of these
diseases, one obvious approach to maintaining the health
of older people would be to intervene in the underlying
ageing process itself. The intrinsic rate of ageing can be
drastically altered by (presumably complex) genetic
change, because there is great diversity in the natural
lifespans of animals, even when they are brought into
environments where they are largely protected from ex-
trinsic hazards. For instance, among mammals, bats, pri-
mates, and whales are notably long lived [5]. Scientific
discoveries from research into ageing in recent years have
also suggested that intervening in human ageing is more
plausible than it once seemed. Although ageing is compli-
cated and variable, with diverse kinds of damage and
pathology accumulating in a way that varies between both
different body tissues and individual organisms, the pro-
cess has nonetheless proved to be malleable. Both genetic
mutations and environmental interventions such as al-
tered diet and drugs can increase lifespan and health
during ageing in laboratory organisms (yeast, nematodes,
fruit flies, and mice). Furthermore, despite the very differ-
ent lifespans and lifestyles of these creatures, similar
interventions have proved capable of extending health
span in all, implying some commonalities in the underlying
mechanisms of ageing. Simpler organisms with shorter
lifespans can thus contribute to an understanding of the
mechanisms of mammalian, including human, ageing, and
to the discovery of interventions that could ameliorate it
[6–8].
What makes us age?
The ageing process remains a considerable biological mys-
tery. Virtual immortality of cell lines is clearly possible
because all current life on earth originated from a common
ancestor, as evidenced by the use of a common genetic code.
Germlines, therefore, do not have to die. Also, some mul-
ticellular organisms, such as Hydra and some sea ane-
mones, do not become less able to reproduce or more likely
to die over time [9]. Organisms are generally maintained in
a youthful state during their development and it is only
with the onset of reproduction that the effects of ageing
start to become apparent [8]. However, it is not clear in any
organism how the ageing process starts and which of the
many phenotypes of ageing are causal in the different
aspects of functional decline and risk of ageing-related
diseases. Many features may be bystander effects with
little functional significance, such as the greying of hair.
Homeostatic responses of the organism to ageing-related
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Figure 1. Current and potential future strategies for understanding and preventing
ageing-related diseases. Left: Current strategy tends to research and treat
individual ageing-related diseases separately. Right: Recent research points to
the prospect of research to understand and intervene in the underlying ageing
process as a means for simultaneously preventing multiple diseases of ageing.
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sembled [10]. Common features of ageing include genomic
instability, telomere attrition, epigenetic alterations, loss
of proteostasis, deregulated nutrient-sensing, mitochon-
drial dysfunction, cellular senescence, stem cell exhaus-
tion, and altered intercellular communication. These
hallmarks vary in prominence between different tissues
and are present to differing degrees in different organisms.
Their functional significance and the causal nexus between
them are the subject of intense study. In multicellular
organisms the picture is further complicated by systemic
effects, with one tissue affecting the ageing of others.
Slowing down ageing
Interventions that improve health during ageing and in-
crease lifespan across multiple organisms, including mam-
mals, are of particular interest. They indicate that the
normal ageing process has been targeted and can therefore
reveal both fundamental mechanisms of ageing and poten-
tial drug targets for the prevention of ageing-related dis-
ease. Dietary restriction (DR), a reduction of food intake
short of malnutrition, increases health during ageing in
nearly all organisms so far investigated, including pri-
mates and possibly humans [8]. DR is not a practical
intervention for most humans because compliance with
this rigorous dietary regimen is low. However, recent work
in both animals and humans has suggested that reduced
intake of certain nutrients, particularly specific amino
acids, may be more important than reduced calorie intake
in conferring the health benefits of DR [11]. Furthermore,
altered activity of the key metabolic and endocrine signal-
ling networks that sense nutrients can also improve health
during ageing. Mutations that reduce the activity of insu-
lin/insulin-like growth factor signalling (IIS) and the con-
nected target of rapamycin (TOR) network can extend
lifespan in organisms ranging from yeast to mammals.
There is also a broad-spectrum improvement in the health
of these animals during ageing [7–9]. For instance, mu-
tant-IIS mice show improvements in glucose handling,
immune profile, and motor performance and are protected
against osteoporosis, cataract, and skin problems. Impor-
tantly, there are many potential drug targets in this sig-
nalling network, including several kinases, and
rapamycin, a specific inhibitor of TOR, can extend lifespan
in mice [12].
The IIS/TOR network senses the status of nutrients,
growth factors, and various forms of stress and adjusts
growth, metabolism, and reproduction accordingly. Ex-
treme alterations of its activity can therefore be harmful.
For instance, reduced insulin signalling can cause diabe-
tes. However, it is clear that specific reductions in IIS and
TOR activity (which one being determined possibly by the
magnitude of the reduction or the exact part of the network
affected) can improve overall health during ageing. For
these and other interventions, such as diet and drugs, the
key challenge is to understand exactly how they do it, to
triage away beneficial effects on health from undesirable
side effects. The hallmarks of ageing provide candidate
processes for further detailed analysis [10]. For instance,
experimental work has addressed the potential role of
cellular quality-control processes including autophagy556and proteasomal degradation of damaged proteins and
the maintenance of telomeres in maintaining the health
of the whole organism during ageing.
Mechanistic connections between ageing and ageing-
related disease
The improvements in health during ageing seen in animal
models of slowed ageing provide an excellent context in
which to understand the mechanistic connections between
ageing and ageing-related disease. For instance, in the
fruit fly Drosophila, rapamycin administered to old flies
was recently shown to lower dopamine activity and hence
reverse their natural, age-related fragmentation of night
sleep, a common problem in older humans [13]. The inter-
action between interventions that slow ageing and genetic
models of disease has also proved informative. For in-
stance, in the nematode Caenorhabditis elegans, genetical-
ly reduced IIS protected against the pathology associated
with a worm model of cancer by altering the expression of
genes that were highly enriched with the worm equivalents
of human oncogenes and tumour suppressors, including a
worm orthologue of lysosome-associated transmembrane
protein 4B (LAPTM4B), which stimulates cell proliferation
and inhibits cell death in mammalian cancer [14]. Demen-
tia in humans is proving a particularly intractable feature
of ageing, with the incidence projected to increase to un-
manageable levels in many countries. Mouse genetic mod-
els of this condition have shown that reduced IIS and
rapamycin can ameliorate the associated pathology, and
understanding the detailed mechanisms at work may help
to solve this major medical problem.
Targeting ageing to treat diseases of ageing
Economic analysis has shown that amelioration of
ageing would have enormous health benefits [15]. Specific
Science & Society Trends in Endocrinology and Metabolism November 2014, Vol. 25, No. 11interventions for specific problems of ageing are important
and will continue to be so. What the animal models of slowed
ageing have shown us is that there is also the prospect of a
broad-spectrum preventive medicine for the diseases of
ageing (Figure 1). Rapamycin is an early example of a
licensed drug proving to have a wider therapeutic range
than previously suspected and others such as metformin
and aspirin are starting to show similar features.
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